Key Points
- Guardant Health director Musa Tariq sold 116 shares on May 18 at an average price of $95.96, totaling $11,131.36. The sale was made under a pre-arranged Rule 10b5-1 plan, and Tariq now holds 8,662 shares.
- The stock was trading higher, opening at $98.19 and up 2.6% on the day. Guardant Health has a market cap of $13.02 billion and has traded between $36.36 and $120.74 over the past year.
- Analysts remain mostly positive on GH, with 19 Buy ratings, one Hold, and one Sell. The consensus price target is $129.42, even though the company recently reported a quarterly EPS miss while revenue rose 39.4% year over year.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Musa Tariq sold 116 shares of the business's stock in a transaction on Monday, May 18th. The shares were sold at an average price of $95.96, for a total transaction of $11,131.36. Following the completion of the sale, the director owned 8,662 shares in the company, valued at $831,205.52. This represents a 1.32% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Musa Tariq also recently made the following trade(s):
- On Thursday, April 16th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $84.83, for a total transaction of $9,840.28.
- On Wednesday, March 18th, Musa Tariq sold 348 shares of Guardant Health stock. The shares were sold at an average price of $88.09, for a total transaction of $30,655.32.
Guardant Health Trading Up 2.6%
Shares of Guardant Health stock opened at $98.19 on Wednesday. The stock has a market capitalization of $13.02 billion, a price-to-earnings ratio of -28.96 and a beta of 1.48. Guardant Health, Inc. has a 1-year low of $36.36 and a 1-year high of $120.74. The firm's 50-day moving average price is $89.50 and its two-hundred day moving average price is $98.46.
Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.07). The firm had revenue of $281.27 million for the quarter, compared to the consensus estimate of $269.74 million. The company's revenue was up 39.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.62) EPS. As a group, equities research analysts predict that Guardant Health, Inc. will post -2.87 EPS for the current year.
Hedge Funds Weigh In On Guardant Health
Hedge funds have recently added to or reduced their stakes in the company. V Square Quantitative Management LLC acquired a new stake in Guardant Health in the fourth quarter worth about $27,000. Chesapeake Asset Management LLC bought a new stake in Guardant Health during the 4th quarter worth about $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Guardant Health during the 4th quarter valued at about $31,000. Elyxium Wealth LLC acquired a new position in Guardant Health during the 4th quarter valued at about $35,000. Finally, Parallel Advisors LLC boosted its stake in shares of Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company's stock valued at $36,000 after purchasing an additional 219 shares during the last quarter. Institutional investors own 92.60% of the company's stock.
Analyst Ratings Changes
A number of equities analysts have commented on GH shares. Guggenheim boosted their price objective on Guardant Health from $115.00 to $135.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. Piper Sandler restated an "overweight" rating and issued a $135.00 target price on shares of Guardant Health in a research note on Tuesday, May 12th. BTIG Research lifted their price target on Guardant Health from $140.00 to $145.00 and gave the company a "buy" rating in a report on Friday, February 20th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Guardant Health in a research report on Tuesday, April 21st. Finally, Wells Fargo & Company increased their price objective on shares of Guardant Health from $120.00 to $125.00 and gave the stock an "overweight" rating in a report on Friday, February 20th. Nineteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $129.42.
Check Out Our Latest Analysis on GH
About Guardant Health
(
Get Free Report)
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
